Scottish Medicines Consortium approves Lupin’s NaMuscla® (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM)

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing